Ecstasy is becoming popular once again in the European Union (EU), according to a new report on drugs.With online sales and targeted marketing, there are signs that the drug is resurfacing among a new generation of users, the 2016 European Drug Report has found.According to the report by European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), MDMA – also known as ecstasy – has returned, and is being dubbed the “stimulant of choice” for young people.Ecstasy first established itself in the illegal drug market in the 1990s, but its use declined at the end of the last decade. This was put down to poor drug quality and adulteration.With new ecstacy pills emerging, officials are becoming increasingly concerned at the “dramatic increase” in the potency of the new tablets.Paul Griffiths, EMCDDA’s scientific director, spoke at a news conference and also noted young ecstasy users may be “more naive” about the potentially fatal risks of overheating and dehydration when taking ecstasy.The report found that 2.1 million people aged 15 to 34 had taken ecstasy in the last year – 300,000 more than was first estimated.Griffiths said producers and traffickers are using “sophisticated marketing techniques” to sell more ecstasy.
Some of the new pills entering the market include those that glow in the dark and drugs manufactured for specific events – such as festivals. Some now also feature unique logos that may be playing a part in the rising number of consumers.Authorities believe most ecstasy in the EU is produced in or around the Netherlands.“The MDMA content of tablets has increased since 2010 and is now at an all-time high whilst prices appear to have remained relatively stable,” the report said.Despite ecstasy’s return its use is still dwarfed by the popularity of cannabis, which remains the EU’s biggest-selling drug. It is estimated that in 2013 cannabis generated an annual retail value of £7 billion.Agency figures reveal the retail market for illicit drugs in the EU was at least £18 billion in 2013.Heroin sales are estimated to be the second highest, at £5.1 billion, followed by cocaine at £4.4 billion. Sales of MDMA are believed to total almost £534 million.Cannabis offences, mostly involving use or possession for personal use, account for close to 75% of all drug-related offences in the EU.The agency said online drug sales appear to be growing, representing an “important new challenge for drug policy.”